API | rovalpituzumab tesirine

rovalpituzumab tesirine Report issue

Biologics mAb ADC Experimental

AACT DrugBank PubChem

Active Ingredient History

NOW

Rovalpituzumab tesirine (Rova-T) is an experimental antibody-drug conjugate targeting the protein DLL3 on tumor cells. It was originally developed by Stemcentrx and was purchased by AbbVie. It was tested for use in small-cell lung cancer, but development was terminated after unsuccessful phase III trial. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanism of Action:
Multi-specific: No
Payload: tesirine
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

rovalpituzumab tesirine | sc16ld6.5

Organizations (4)

Research & Development (4)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)

Glioblastoma (Phase 1/Phase 2)

Lymphoma, Large-Cell, Immunoblastic (Phase 2)

Melanoma (Phase 1/Phase 2)

Neoplasms (Phase 2)

Neuroendocrine Tumors (Phase 2)

Pancreatic Neoplasms (Phase 2)

Small Cell Lung Carcinoma (Phase 3)

Thyroid Neoplasms (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 12
# of Trial Organizations: 4

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue